Recent Updates
Recently added Catalysts
NAGE Positive Sentiment

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Monday, August 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168. This collaboration aims to leverage Evotec's expertise in drug discovery and development. The initiative aligns with Niagen's focus on NAD+ and healthy aging, potentially leading to significant advancements in this area.
Price reaction · baseline $3.4 (2026-07-31 close) · hit pre-market · clean, no other NAGE news in the window
day 0 close · peak
+3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Evotec enhances development capabilities.
  • Focus on NAD+ aligns with growing interest in healthy aging.
  • Potential for significant advancements in preclinical development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~165 mo
Minimal dilution risk
Lead asset
NiagenPlus
Phase 1 · Healthy Volunteer

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N

Frequently Asked Questions

What is the purpose of the collaboration with Evotec?

The collaboration aims to advance the preclinical development of NB4168.

What area does Niagen Bioscience focus on?

Niagen focuses on NAD+ and the science of healthy aging.

Who is supporting Niagen in the development of NB4168?

Evotec is supporting Niagen as a contract research organization.

What is NB4168 related to?

NB4168 is related to the research and development of NAD+.

ShareAdd on Google
Tags: NAGE Viatris Investor Conferences Healthcare Niagen Bioscience Evotec NB4168 NAD+ healthy aging
Last updated: Aug 3, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
~165 mo
Minimal dilution risk
Lead asset
NiagenPlusPhase 1
Healthy Volunteer →